# Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

> **NCT05179889** · PHASE2,PHASE3 · RECRUITING · sponsor: **Chungnam National University Hospital** · enrollment: 308 (estimated)

## Conditions studied

- Colon Cancer Stage III

## Interventions

- **DRUG:** mFOLFIRINOX
- **DRUG:** mFOLFOX 6

## Key facts

- **NCT ID:** NCT05179889
- **Lead sponsor:** Chungnam National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-06
- **Primary completion:** 2028-07-05
- **Final completion:** 2031-03-15
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05179889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05179889, "Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05179889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*